Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa

Michelle J Groome, Sung-Sil Moon, Daniel Velasquez, Stephanie Jones, Anthonet Koen, Nadia van Niekerk, Baoming Jiang, Umesh D Parashar & Shabir A Madhi

Objective To investigate the effect of abstention from breastfeeding, for an hour before and after each vaccination, on the immune responses of infants to two doses of rotavirus vaccine.

Methods In Soweto, South Africa, mother–infant pairs who were uninfected with human immunodeficiency virus (HIV) were enrolled as they presented for the “6-week” immunizations of the infants. Each infant was randomly assigned to Group 1 – in which breastfeeding was deferred for at least 1 h before and after each dose of rotavirus vaccine – or Group 2 – in which unrestricted breastfeeding was encouraged. Enzyme-linked immunosorbent assays were used to evaluate the titres of rotavirus-specific IgA in samples of serum collected from each infant immediately before each vaccine dose and 1 month after the second dose. Among the infants, a fourfold or greater increase in titres of rotavirus-specific IgA following vaccination was considered indicative of seroconversion.

Findings The evaluable infants in Group 1 (n = 98) were similar to those in Group 2 (n = 106) in their baseline demographic characteristics and their pre-vaccination titres of anti-rotavirus IgA. After the second vaccine doses, geometric mean titres of anti-rotavirus IgA in the sera of Group-1 infants were similar to those in the sera of Group-2 infants (P = 0.685) and the frequency of seroconversion in the Group-1 infants was similar to that in the Group-2 infants (P = 0.485).

Conclusion Among HIV-uninfected South African infants, abstention from breastfeeding for at least 1 h before and after each vaccination dose had no significant effect on the infants’ immune response to a rotavirus vaccine.

Introduction

Rotavirus is the leading cause of severe gastroenteritis in young children. It was estimated that 453 000 of the deaths – or 37% of all of the diarrhoea-related deaths – that occurred globally in 2008 were attributable to rotavirus infection. In South Africa in 2009, diarrhoea was the leading cause of death among children younger than 5 years and accounted for 18% of the deaths in this age group. In a review of relevant published studies, the median rate of rotavirus detection reported among children hospitalized for diarrhoea in South Africa was found to be 24% (range: 13–55%).

Two live oral vaccines against rotavirus – Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq® (Merck Vaccines, Whitehouse Station, United States of America) – have been licensed for international use. Both are being introduced into national immunization programmes, in accordance with World Health Organization recommendations. Clinical trials have demonstrated that the two vaccines are highly effective against severe rotavirus gastroenteritis in middle- and high-income countries in Europe and Latin America. However, the vaccines appear to show relatively lower efficacy and immunogenicity in some low- to middle-income countries in Africa and Asia. In an African study, two or three doses of Rotarix® were found to reduce the incidence of severe rotavirus gastroenteritis during the first year of life by 77% in South Africa and 49% in Malawi. RotaTeq® was found to have vaccine efficacies – again measured against severe rotavirus disease in the first year of life – of 64% in a multicentre trial in Ghana, Kenya and Mali and of 51% in a separate study based in Bangladesh and Viet Nam. Other live oral vaccines, such as those against polio and cholera and earlier potential rotavirus vaccines, have also shown relatively lower efficacies when tested in low-income countries.

There are several possible reasons why rotavirus vaccines might show relatively lower efficacies in low- and middle-income countries in Africa and Asia. These include interference from high levels of rotavirus-specific antibodies that infants may acquire – either transplacentally or via breastfeeding – from their mothers; the co-administration of oral polio vaccine; micronutrient deficiency; enteric co-infections and other concurrent diseases, such as infection with human immunodeficiency virus (HIV). In trials of earlier vaccine candidates for the control of rotavirus infection, seroconversion was sometimes found to be less common among breastfed infants than among non-breastfed infants who had been given the same number of doses of the vaccine. Although there appears to be no evidence to indicate that, during the first year of life, Rotarix® or RotaTeq® shows lower efficacy among breastfed infants than among infants given only formula milk, there has been no detailed attempt to explore this possibility.

Titres of anti-rotavirus IgA in sera of infants and levels of lactoferrin and rotavirus-specific neutralizing activity in the breast milk of mothers have been shown to vary by setting. For example, breast milk samples from Indian and South African women with low socioeconomic status tend to have lower titres of anti-rotavirus IgA in sera of infants and levels of lactoferrin and rotavirus-specific neutralizing activity in the breast milk of mothers have been shown to vary by setting. For example, breast milk samples from Indian and South African women with low socioeconomic status tend to have

Abstracts in العربية, 中文, Français, Русский и Español at the end of each article.

References

6 Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, PO Box 90753, Berrissham, 2013, Gauteng, South Africa.
7 Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, United States of America.
8 Correspondence to Michelle J Groome (e-mail: groome@mpru.co.za).
9 Submitted: 19 August 2013 – Revised version received: 10 December 2013 – Accepted: 10 December 2013 – Published online: 4 February 2014

higher titres of anti-rotavirus IgA and neutralizing activity than those collected from women in the United States.\textsuperscript{18–20} Such differences may partially explain why current rotavirus vaccines have relatively poor efficacy in low-income settings. Among infants, the efficacies of both Rotarix\textsuperscript{®} and RotaTeq\textsuperscript{®} appear to be positively correlated with serum titres of rotavirus-specific IgA.\textsuperscript{20}

The main objectives of the present study were to determine the titres of rotavirus-specific IgA in infant serum, maternal serum and maternal breast milk in a cohort of HIV-uninfected South African mother–infant pairs, and to investigate the effect of abstention from breastfeeding at the time of vaccination on the immunogenicity of the Rotarix\textsuperscript{®} vaccine.

**Methods**

**Participants and specimen collection**

We conducted a prospective, randomized, longitudinal cohort study of consenting, healthy, HIV-uninfected mother–infant pairs. The mothers and infants were enrolled – between 2 December 2009 and 9 April 2010 – as they presented for their “6-week” routine immunization visits at Diepkloof Primary Health Clinic, Soweto, South Africa. Follow-up continued until August 2010. Infants were considered for enrolment if they were aged 5 to 8 weeks, were being breastfed, had received no vaccines except oral polio vaccine and bacille Calmette–Guerin (BCG) at birth and had mothers who had been found seronegative for HIV after week 24 of gestation. Infants with known underlying immunosuppressive conditions and infants showing failure to thrive – that is, infants who fell below the third centile for weight-for-age or had dropped more than two weight-for-age centiles since birth – were excluded. Enrolled infants were randomized into two groups, known simply as Group 1 and Group 2. Mothers of Group 1 infants were instructed not to breastfeed their infants for at least 1 h before and after administration of each dose of rotavirus vaccine. Unrestricted breastfeeding was encouraged among the mothers of Group 2 infants. Breastfeeding of the enrolled infants was monitored at the study clinic as the mother–infant pairs presented for vaccination. The laboratory personnel who tested sera and breast-milk samples were blind to the group allocation.

All vaccines were provided according to the standard schedule of the expanded programme on immunization in South Africa. According to this schedule, each South African infant should be given trivalent oral polio vaccine (OPV-Merieux; Sanofi Pasteur, Lyon, France) at 6 weeks of age, a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and *Haemophilus influenzae* type b conjugate vaccine (Pentaxim; Sanofi Pasteur) and a hepatitis B vaccine (Heberbiovac HB; Heber Biotec, Havana, Cuba) at 6, 10 and 14 weeks, and rotavirus vaccine (Rotarix\textsuperscript{®}) and a heptavalent pneumococcal conjugate vaccine (Prevenar; Wyeth, Madison, USA) at 6 and 14 weeks.

Samples were collected from the infants immediately before the first and second doses of Rotarix\textsuperscript{®} and 1 month after the second dose. Samples of serum and breast milk were collected from the mothers shortly before their infants received each dose of Rotarix\textsuperscript{®}. All of the sera and breast-milk samples were given code numbers to hide the identities of their donors. The samples were kept frozen at −70 °C until they were shipped – on solid carbon dioxide – to the Division of Viral Diseases of the United States Centers for Disease Control and Prevention, in Atlanta, United States, where they were investigated. Titres of anti-rotavirus IgA in all of the sera and breast milk samples, titres of anti-rotavirus IgG in the sera collected from the infants before the first dose of Rotarix\textsuperscript{®}, and levels of rotavirus-specific neutralizing antibodies in the breast-milk samples were evaluated.

The protocol was reviewed and approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M090824). Written informed consent was obtained from a parent of each enrolled infant. The trial was registered on the South African National Clinical Trial Register (DOH-27–0511–2991).

**Specimen testing**

Titres of rotavirus-specific IgA were determined in enzyme-linked immunosorbent assays.\textsuperscript{18} For these assays, microplate wells were coated with rabbit hyperimmune serum to rhesus rotavirus and incubated either with diluted Rotarix\textsuperscript{®} strain or 5% (v/v) skim milk in phosphate-buffered saline (PBS). After washing, breast milk diluted 1:5–1:5120 in diluent buffer – PBS supplemented with 1% (v/v) skim milk and 0.5% (v/v) of a 10% solution of polyoxyethylene ether W1 – or serum diluted 1:20–1:10 240 in the same buffer – was added to each well, followed by biotin-conjugated goat anti-human IgA antibodies (KPL, Gaithersburg, USA). After incubation and washing, Extravidin (Sigma-Aldrich, St Louis, USA) was added to the wells and incubated, and then the reactions were developed with 3,3’,5,5’-tetramethylbenzidine (Sigma-Aldrich) and stopped with 1 M HCl. The optical density of the contents of each well was determined, at 450 nm, in a plate reader (MRX Revelation; Dynex Technologies, Chantilly, USA).

Anti-rotavirus IgA titres were calculated as the reciprocals of the highest dilutions that gave mean optical densities that were greater than the cut-off value. The cut-off value was set three standard deviations above the mean optical density for the negative-control wells. Rotavirus-specific IgG was tested and analysed in the same manner as IgA except that biotin-conjugated goat anti-human IgG antibodies (KPL) were used and 0.5% (v/v) normal rabbit serum was added to the biotin-conjugate solution.

The level of rotavirus-specific neutralizing activity in each breast-milk sample was evaluated in a microneutralization assay.\textsuperscript{14} For this, a twofold serial dilution of each breast-milk sample was prepared and 50 μl of each dilution were mixed with an equal volume of trypsin-activated Rotarix\textsuperscript{®} vaccine virus in the well of a microtitre plate – to yield a concentration of 4000 focus-forming units per well – and incubated at 37 °C for 1 h. The contents of each well were then placed on a PBS-washed monolayer of MA104 cells that had been grown in a 96-well plate. After another incubation at 37 °C for 1 h, the plate was washed with PBS and 100 μl of Iscove’s modified Dulbecco’s medium (Invitrogen, Carlsbad, USA) containing 5 μg trypsin per ml were added to each well. After incubation at 37 °C for 20 hours, 15 μl of 37% (w/v) formaldehyde were added to each well and left at 4 °C for 30 minutes. Rotavirus antigen in the MA104 cells was detected by incubating plates with a rabbit anti-rhesus-rotavirus hyperimmune serum, then anti-rabbit IgG labelled with horseradish peroxidase, and finally with 3,3’,5,5’-tetramethyl-
benzidine. The neutralizing titre in a breast milk sample was determined as the reciprocal of the highest dilution that showed a reduction in the absorbance value – relative to that in the virus-only controls – of more than 70%.

**Sample size**

The study was powered to detect at least a 20% higher frequency of seroconversion among the Group 1 infants than among the Group 2 infants. It was assumed that about 55% of the Group-2 infants would seroconvert in terms of their anti-rotavirus IgA, since 57% of infants given two doses of the vaccine had previously shown such seroconversion in a trial of the efficacy of Rotarix® in South Africa.a After setting a 5% significance level and 80% power and allowing for 20% loss to follow-up, our aim was to enrol at least 123 infants into each of the two study groups.

**Statistical analysis**

For the allocation of infants to each study group, a randomization list was generated using the SAS software package (SAS Institute, Cary, USA). Data analysis was performed using version 12.1 of the STATA package (StataCorp LP, College Station, USA). A P-value of 0.05 or lower was considered statistically significant. Titres were log-transformed to give a better approximation to a normal distribution. Geometric mean titres were calculated. Continuous variables were compared using two-sample Student’s t-tests – if the data were normally distributed – or Wilcoxon rank-sum tests. Temporal changes in the log-transformed titres within a single study group were investigated in t-tests for matched pairs. Categorical variables were compared using χ² tests. For the calculation of geometric mean titres, titres of anti-rotavirus IgA in serum that fell below 20 were included in the final analysis (n = 7). Even the data for infants who had pre-vaccination titres of anti-rotavirus IgA in serum that exceeded 20 were included in the final analyses. Seroconversion was defined as a fourfold or greater increase in anti-rotavirus IgA titre compared with the titre recorded before the first dose of Rotarix®.

**Results**

In total, 250 infants were enrolled at a median age of 6.1 weeks. At enrolment, each of these infants received a first dose of Rotarix®, oral polio vaccine and other, scheduled, childhood vaccines. Although 125 infants were allocated to each study group, only 98 (78%) of those allocated to Group 1 and 106 (85%) of those allocated to Group 2 were fully adherent to the study protocol and included in the final analysis (Fig. 1). No significant differences were observed – in infant age at enrolment, sex or birth weight or baseline titres of anti-rotavirus IgA and IgG in the infants and their mothers – between the “eligible” infants who were included in the final analysis and the other enrolled infants (data not shown).

In terms of sex, birth weight and age at vaccination, the evaluable infants in Group 1 were similar to those in Group 2 (Table 1). The second Rotarix® dose was administered at a median of 9.1 weeks (range: 5.4–16.9) after the first dose and subsequent immunogenicity was measured a median of 4.5 weeks (range: 3.9–8.3) later. The timing of these events was similar in the two study groups. When measured before the first vaccine dose, the geometric mean titres of anti-rotavirus IgG and IgA in infant sera and anti-rotavirus IgA in maternal sera and breast milk samples and the geometric mean neutralizing titres in breast milk were also similar in the two study groups (Table 1). There were no significant between-group differences in the geometric mean titres of anti-rotavirus IgA in infant sera measured at the first (P = 0.612) or second doses (P = 0.685) of Rotarix® (Table 1). However, in both the Group 1 infants and the Group 2 infants, such mean titres were higher after both the first dose of Rotarix® (53.4 and 46.0, respectively) and the second (137.7 and 122.7, respectively) than the titres recorded before the first dose (14.2 and 14.6, respectively). These within-group temporal changes were all statistically significant (P < 0.001).

Compared with the values recorded at baseline, the maternal sera and breast milk samples collected after the infants had received their first dose of Rotarix® also showed significantly higher geometric mean titres – of anti-rotavirus
Table 1. Comparison of mother–infant pairs assigned to two arms of a study on the effect of breastfeeding on the immunogenicity of rotavirus vaccine, South Africa, 2009–2010

<table>
<thead>
<tr>
<th>Infants/mothers</th>
<th>Group†</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. evaluated in full</td>
<td>98</td>
<td>106</td>
</tr>
<tr>
<td>Males, no. (%)</td>
<td>55 (56.1)</td>
<td>57 (53.8)</td>
</tr>
<tr>
<td>Mean birth weight, kg (SD)</td>
<td>3.0 (0.5)</td>
<td>3.1 (0.5)</td>
</tr>
<tr>
<td>Median age, weeks (range)</td>
<td>6.3 (5.7–7.7)</td>
<td>6.1 (5.9–7.3)</td>
</tr>
<tr>
<td>On enrolment</td>
<td>15.7 (11.6–23.4)</td>
<td>15.3 (13.9–19.9)</td>
</tr>
<tr>
<td>When investigated after first vaccine dose</td>
<td>20.6 (17.4–27.4)</td>
<td>20.1 (18.0–24.1)</td>
</tr>
<tr>
<td>Serum anti-rotavirus IgG, GMT (95% CI)</td>
<td>1508.6 (1194.8–1904.9)</td>
<td>1524.7 (1220.4–1904.9)</td>
</tr>
<tr>
<td>Serum anti-rotavirus IgA, GMT (95% CI)</td>
<td>14.2 (9.8–20.6)</td>
<td>14.6 (10.0–21.5)</td>
</tr>
<tr>
<td>On enrolment</td>
<td>53.4 (36.7–77.7)</td>
<td>46.0 (29.7–71.3)</td>
</tr>
<tr>
<td>After first dose of vaccine</td>
<td>137.7 (90.2–210.2)</td>
<td>122.7 (84.6–177.9)</td>
</tr>
<tr>
<td>Breast-milk anti-rotavirus IgA, GMT (95% CI)</td>
<td>26.2 (15.6–44.0)</td>
<td>27.4 (16.5–45.5)</td>
</tr>
<tr>
<td>On enrolment</td>
<td>164.0 (103.8–259.1)</td>
<td>186.8 (125.4–278.1)</td>
</tr>
<tr>
<td>After infant received first dose of vaccine</td>
<td>39.3 (28.5–51.6)</td>
<td>42.4 (32.2–55.7)</td>
</tr>
<tr>
<td>Breast-milk neutralizing activity, GMT (95% CI)</td>
<td>52.2 (39.3–69.2)</td>
<td>56.4 (41.4–76.8)</td>
</tr>
<tr>
<td>On enrolment</td>
<td>8.8 (6.0–13.0)</td>
<td>8.3 (6.0–11.5)</td>
</tr>
<tr>
<td>After infant received first dose of vaccine</td>
<td>19.1 (12.9–28.3)</td>
<td>21.5 (14.9–31.1)</td>
</tr>
</tbody>
</table>

Cl, confidence interval; GMT, geometric mean titre; SD, standard deviation.

† Each infant was randomly assigned to either Group 1 – in which there was an abstention from breastfeeding for at least 1 h before and after each dose of rotavirus vaccine – or Group 2 – in which unrestricted breastfeeding was encouraged.

‡ No data available for four infants (one in Group 1).

§ No data available for 21 infants (11 in Group 1).

‖ No data available for one mother of an infant in Group 1.

¶ No data available for one mother of an infant in Group 2.

‖‖ No data available for two mothers (one of an infant in Group 1).

There has been much speculation about the reasons for the relatively low efficacy and immunogenicity of rotavirus vaccines in low- and middle-income countries in Africa and Asia. One hypothesis is that rotavirus-specific antibodies and other neutralizing factors present in breast milk may diminish a breastfed infant’s immune responses to a rotavirus vaccine – by lowering the effective titre of vaccine delivered to the infant’s gut. This hypothesis was supported by the results of two recent in vitro studies in which levels of lactoferrin, anti-rotavirus IgA and neutralizing activity in breast milk samples from mothers who were breastfeeding their infants were evaluated. Breast milk with low titres of rotavirus-specific neutralizing activity did not seem to affect the vaccine virus but milk with high titres could neutralize the vaccine virus, even when diluted. These observations indicated that a short abstention from breastfeeding at the time of each vaccination could potentially improve the immunogenicity of a rotavirus vaccine. However, the results of the present study indicate that abstaining from breastfeeding for at least an hour before and after each of two doses of Rotarix® had no significant effect on the frequency of seroconversion among the vaccinated infants or the titres of anti-rotavirus IgA in the sera of the same infants.

The results of earlier, related in vivo studies – in which the effects of breast milk on immunogenicity and seroconversion after the administration of candidate vaccines against rotavirus were investigated – were equivocal. Although each of two meta-analyses led to the conclusion that breastfeeding did significantly reduce the immune response to a single dose of rhesus rotavirus vaccine, the data analysed came from studies that differed markedly in terms of the number of vaccine doses,

Michelle J Groome et al.

Breastfeeding and immunogenicity of rotavirus vaccine in South Africa


241
The overall frequency of seroconversion observed in the present study following the second dose of Rotarix® – 61% – is reassuring, bearing in mind that the rotavirus vaccination schedule currently followed in South Africa, of doses at 6 and 14 weeks of age, has not yet been studied in clinical trials. This frequency of seroconversion is similar to the values observed in the South African trial of the clinical efficacy of Rotarix®, which were 57.1% (95% CI: 44.7–68.9) after two doses and 66.7% (95% CI: 54.0–77.8) after three doses. However, comparisons between the efficacy trial and the present study must be made with caution since different assays to assess immunogenicity were used in the two investigations. In the efficacy trial, a commercial enzyme-linked immunosorbent assay with a cut-off point for seroconversion of 20 “units” per ml was used, whereas we used another immunosorbent assay and defined seroconversion as a fourfold or greater increase in an infant’s titres of anti-rotavirus IgA. The dosing schedule used in the two investigations also differed: the two-dose group in the efficacy trial received Rotarix® at 6 and 10 weeks of age, while in the present study the same vaccine was given at approximately 6 and 14 weeks of age. The identification of a correlate of protection after rotavirus vaccination has proven difficult, mainly because of differences between the relevant studies in terms of vaccine type, dose schedule, regional pre-immunization titres, laboratory assays and the impact of natural exposure. However, serum titres of antirotavirus IgA have been identified as one important predictor of protection.

There were some limitations to our study. The second dose of Rotarix® could only be given to some of the infants one month later than scheduled because the vaccine stocks became exhausted between April and May of 2010. This meant that not all infants received two doses before the onset of the rotavirus season in 2010. Towards the end of our study, therefore, there may have been natural rotavirus in circulation and this could have affected the titres of the antibodies that we investigated, in both the infants and the mothers. However, the level of natural exposure to rotavirus would have been similar in the two study groups and not likely to have affected our conclusions.
We only assessed whether abstention from breastfeeding for about 1 h before and after each vaccination had an effect on immunogenicity. Although it remains possible that a more prolonged abstention may have had a greater impact, leaving an infant unfed for more than 2 h may not be programmatically possible or acceptable. Although the mothers of Group 2 infants were encouraged to breastfeed their infants soon after the vaccines were given, the length of each first feed after the vaccination was not recorded. As suckling is often used as a comfort, a full feed may not have been given at this time. The interaction between vaccine and breast milk in the Group 2 infants may therefore have been less than the maximum possible.

The present study was designed to detect a 20% difference in the frequency of seroconversion between the two groups of infants. A larger sample size may have allowed detection of a significantly different magnitude. However, policy-makers are unlikely to promote changes in national breastfeeding habits if such changes only lead to small increases in the immunogenicity of rotavirus vaccines given to infants.

Abstention from breastfeeding for 1 h before and after vaccination does not appear to have any significant effect on the immune response to Rotarix® in a low- to middle-income African setting. The reason or reasons that oral rotavirus vaccines appear to have relatively low efficacy in low-income settings – which may include enteric co-infections and concurrent medical conditions – require further investigation. The potential for boosting the efficacy of such vaccines – for example, by zinc supplementation or the co-administration or probiotics – and other approaches to rotavirus vaccination – such as vaccines derived from neonatal strains or parenteral vaccines – should also be investigated.

Acknowledgements

We thank the mothers and children whom we investigated for participating in our study. We are also grateful to the staff of the University of the Witwatersrand’s Respiratory and Meningeal Pathogens Research Unit – for their dedicated work; to the doctors who assisted with participant enrolment and follow-up; and to Elizabeth R Zell – for her valuable discussions. MJG, AK, NvN and SAM have dual appointments with the Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa. SAM also has a dual appointment with the National Institute for Communicable Diseases, Centre for Vaccines and Immunology, Sandringham, South Africa.

Funding: This work was supported by the Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand and the United States Centers for Disease Control and Prevention.

Competing interests: None declared.
Breastfeeding and immunogenicity of rotavirus vaccine in South Africa

Michelle J Groome et al.

Effet de l’allaitement sur l’immunogénéricité du vaccin oral vivant atténué contre le rotavirus humain: un essai randomisé parmi les nourrissons séronégatifs à Soweto, en Afrique du Sud

Objectif Étudier l’effet de l’abstention de l’allaitement, une heure avant et après chaque vaccination, sur les réactions immunitaires des nourrissons à deux doses de vaccin contre le rotavirus.

Méthodes À Soweto, en Afrique du Sud, des couples mère-enfant non infectés par le virus de l’immunodéficience humaine (VIH) ont été inscrits à cette étude, alors qu’ils se présentaient pour les vaccinations des nourrissons de 6 semaines. Chaque enfant a été placé au hasard dans le groupe 1 – au sein duquel l’allaitement était reporté au moins d’une heure avant et après chaque dose de vaccin contre le rotavirus – ou dans le groupe 2 – au sein duquel l’allaitement sans restriction a été encouragé. Des dosages immuno-enzymatiques ont été utilisés pour évaluer les titres d’IgA spécifiques du rotavirus dans des échantillons de sérum prélevés chez chaque enfant immédiatement avant chaque dose de vaccin et un mois après la deuxième dose. Chez les nourrissons, une augmentation par 4 ou plus des titres d’IgA spécifiques du rotavirus après la vaccination a été considérée comme une indication de séroconversion.

Résultats Les nourrissons évaluables du groupe 1 (n = 98) étaient similaires à ceux du groupe 2 (n = 106) en ce qui concernait leurs caractéristiques démographiques de base et leurs titres d’IgA anti-rotavirus avant la vaccination. Après les deuxièmes doses de vaccin, les titres moyens géométriques d’IgA anti-rotavirus du sérum des nourrissons du groupe 1 étaient semblables à ceux du sérum des nourrissons du groupe 2 (P = 0,685), et la fréquence de séroconversion des nourrissons du groupe 1 était semblable à celle des nourrissons du groupe 2 (P = 0,485).

Conclusion Chez les nourrissons non infectés par le VIH en Afrique du Sud, l’abstention de l’allaitement pendant au moins une heure avant et après chaque dose de vaccination n’a eu aucun effet significatif sur la réaction immunitaire des nourrissons à un vaccin contre le rotavirus.
Breastfeeding and immunogenicity of rotavirus vaccine in South Africa

Michelle J Groome et al.

los títulos de IgA específica de rotavirus tras la vacunación se consideró indicativo de seroconversión.

Resultados
Las características demográficas de base y los títulos de vacunación previa de la IgA antirrotavirus de los lactantes evaluables del Grupo 1 (n = 98) fueron similares a los del Grupo 2 (n = 106). Tras la segunda dosis de la vacuna, los títulos de la media geométrica de la IgA antirrotavirus en los sueros de los lactantes del Grupo 1 eran similares a los de los sueros de los lactantes del Grupo 2 (P = 0.685) y la frecuencia de la seroconversión en los lactantes del Grupo 1 fue similar a la de los lactantes del Grupo 2 (P = 0.485).

Conclusion
Entre los lactantes sudáfrica infectados por el VIH, la abstención a la lactancia materna durante al menos 1 hora antes y después de cada dosis de la vacuna no tuvo efectos importantes en la respuesta inmune de los lactantes a la vacuna contra el rotavirus.

References